Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Diovan Becomes Best-Selling Drug in April-June: IMS Japan
September 6, 2010
- Homeopathy Has No Scientific Grounds: SCJ
September 6, 2010
- Doctors Hope for Entry of Major Pharmas into Generics Market: Survey
September 6, 2010
- IBD Market to Grow to US$5.6 Bil. in 2019: Datamonitor
September 6, 2010
- Kyowa Kirin Withdraws Application for KW-2246
September 6, 2010
- Questionnaires on Use of Generics to Be Reconsidered
September 6, 2010
- JPMA Calls For Reduction in Effective Corporate Tax Rate to Int'l Standard
September 6, 2010
- Average PMDA Staff Member Earns ¥7,223,000 per Year
September 6, 2010
- Kyowa Kirin Launches Nesp Inj. Plastic Syringe
September 6, 2010
- 3 Switch OTC Drugs Recommended for Approval
September 6, 2010
- Ain Pharmaciez to Strengthen Tie with 7&i HD
September 6, 2010
- General Consumers Show Great Interest in Switch OTC Drugs: JSMI Survey
September 6, 2010
- CDFS Withholds Recommendation of Approval for Liovel
September 6, 2010
- Sales of Class 1 OTC Drugs Up for the 1st Time since PAL Amendment: JSMI
September 6, 2010
- Treakisym from SymBio Recommended for Approval
September 6, 2010
- Teijin: Maintains Top Market Share for Osteoporosis Drugs
August 30, 2010
- Canakinumab, KW-0761 Designated as Orphan Drugs
August 30, 2010
- Vectibix Fails to Prolong OS in Head and Neck Cancer
August 30, 2010
- Pfizer Applies for Its 1st Generics Aiming at Listing in 2011
August 30, 2010
- Meiji Seika: Sales Up 16.6% Driven by New Drugs
August 30, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…